Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

It's worth taking a second look at the healthcare giant.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

Pfizer Inc. remains a Strong Buy, offering compelling value with a 6.32% dividend yield and a P/E Non-GAAP of 8.43. Learn ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Shares of Pfizer Inc. PFE rose 3.92% to $26.78 Wednesday, on what proved to be an all-around mixed trading session for the ...

There are fears that stocks are overvalued right now, and some data backs this up. This could lead to a market crash, though we can't be certain. Buying shares of undervalued companies with strong ...

In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...